AI assistant
UroGen Pharma Ltd. — Director's Dealing 2026
Feb 11, 2026
32312_dirs_2026-02-11_b2e01c76-1b14-451b-9cd4-64ce8991db1a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2026-01-31
Reporting Person: Smith Jason Drew (General Counsel)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2026-01-31 | Ordinary Shares | M | 5500 | — | Acquired | 55472 | Direct |
| 2026-02-03 | Ordinary Shares | S | 2654 | $19.69 | Disposed | 52934 | Direct |
| 2026-01-31 | Ordinary Shares | M | 3333 | — | Acquired | 58805 | Direct |
| 2026-02-03 | Ordinary Shares | S | 1608 | $19.69 | Disposed | 51326 | Direct |
| 2026-01-31 | Ordinary Shares | M | 6667 | — | Acquired | 49972 | Direct |
| 2026-02-03 | Ordinary Shares | S | 3217 | $19.69 | Disposed | 55588 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2026-01-31 | Restricted Stock Units | $ | M | 5500 | Disposed | Ordinary Shares (5500) | Direct | |
| 2026-01-31 | Restricted Stock Units | $ | M | 3333 | Disposed | Ordinary Shares (3333) | Direct | |
| 2026-01-31 | Restricted Stock Units | $ | M | 6667 | Disposed | Ordinary Shares (6667) | Direct | |
| 2026-01-31 | Restricted Stock Units | $ | A | 32609 | Acquired | Ordinary Shares (32609) | Direct |
Footnotes
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
F2: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
F3: The reporting person was granted RSUs on January 31, 2025 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2026.
F4: The reporting person was granted RSUs on January 31, 2023 representing 20,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2024.
F5: The reporting person was granted RSUs on January 31, 2024 representing 16,500 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2025.
F6: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2027, January 31, 2028 and January 31, 2029.